X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The funding will be used to advance the Phase 1 study of AffyImmune’s lead asset, AIC100, for the treatment of anaplastic thyroid cancer and refractory poorly differentiated thyroid cancer.
Lead Product(s): AIC100
Therapeutic Area: Oncology Product Name: AIC100
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: ORI Capital
Deal Size: $30.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing October 07, 2021
Details:
The FDA's Fast Track designation is designed for AIC100 facilitate development and expedite review of drug candidates to treat serious conditions and address an unmet medical need.
Lead Product(s): AIC100
Therapeutic Area: Oncology Product Name: AIC100
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Weill Cornell Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Details:
The study is being conducted at Weill Cornell Medicine. Unlike most CAR-T cell products, AIC100 was designed to specifically target tumor cells overexpressing the target (ICAM-1) while avoiding normal cells expressing lower levels.
Lead Product(s): AIC100
Therapeutic Area: Oncology Product Name: AIC100
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
